Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering tr...

Full description

Saved in:

Bibliographic Details
Published in:	European heart journal Vol. 43; no. 14; pp. 1401 - 1412
Main Authors:	Tardif, Jean-Claude, Karwatowska-Prokopczuk, Ewa, Amour, Eric St, Ballantyne, Christie M, Shapiro, Michael D, Moriarty, Patrick M, Baum, Seth J, Hurh, Eunju, Bartlett, Victoria J, Kingsbury, Joyce, Figueroa, Amparo L, Alexander, Veronica J, Tami, Joseph, Witztum, Joseph L, Geary, Richard S, O’Dea, Louis St L, Tsimikas, Sotirios, Gaudet, Daniel
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 06.04.2022
Subjects:	Apolipoprotein C-III Cardiovascular Diseases - prevention & control Cholesterol Heart Disease Risk Factors Humans Hypertriglyceridemia - complications Hypertriglyceridemia - drug therapy Lipoproteins - therapeutic use Risk Factors Triglycerides Cardiovascular disease Antisense apoC-III Cardiovascular risk factors Hypertriglyceridaemia Atherosclerosis
ISSN:	0195-668X, 1522-9645, 1522-9645
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!